Presentation is loading. Please wait.

Presentation is loading. Please wait.

Comment www.thelancet.com www.thelancet.com Vol 377 February 12, 2011 Stemming the global tsunami of cardiovascular disease.

Published byDominic Lewis Modified over 10 years ago

Similar presentations

Presentation on theme: "Comment www.thelancet.com www.thelancet.com Vol 377 February 12, 2011 Stemming the global tsunami of cardiovascular disease."— Presentation transcript:

1

2 Comment www.thelancet.com www.thelancet.com Vol 377 February 12, 2011 Stemming the global tsunami of cardiovascular disease

3

4 An epidemic of risk factors for cardiovascular disease The Lancet, Volume 377, Issue 9765, Page 527, 12 February 2011

5 INFLAMACION Y ENFERMEDAD CARDIOVASCULAR

6

7

8

9

10 CRP: star trekking the galaxy of risk markers

11

12 Editorial C reactive protein and the risk of cardiovascular disease

13 Are clearly linked but a causal association is unlikely Editorial

14

15

16

17

18 Figure 2

19

20

21

22

23

24

25

26 MICROBIOMA HUMANO Y ENFERMEDAD CARDIOVASCULAR

27

28

29

30

31

32

33

34

35

36 LDL Y ENFERMEDAD CARDIOVASCULAR: MÁS ALLÁ DE LAS ESTATINAS

37

38

39

40

41

42

43

44

45

46

47

48 HDL Y ENFERMEDAD CARDIOVASCULAR

49 HDL and Cardiovascular-Disease Risk Time for a New Approach? N Engl J Med 2011; 364:170-171 January 13, 2011 Editorial Jay Heinecke, M.D.

50 Clinical Implications of Basic Research Sorting Out Cholesterol and Coronary Artery Disease Patrick Linsel-Nitschke, M.D., Nilesh J. Samani, M.D., M.B., Ch.B., and Heribert Schunkert, M.D. N Engl J Med 2010; 363:2462-2463

51 Sortilin 1 and the Risk of Coronary Disease. Linsel-Nitschke P et al. N Engl J Med 2010;363:2462-2463.

52 EPIGENÉTICA Y ENFERMEDAD CARDIOVASCULAR

53

54

55

56

57 INSULINORESISTENCIA Y ENFERMEDAD CARDIOVASCULAR

58 A Comparison of PPARγ Activity in Lean and Obese Persons. Kahn BB, McGraw TE. N Engl J Med 2010;363:2667-2669.

59 NUTRICIÓN Y ENFERMEDAD CARDIOVASCULAR

60 Volume 362:2102-2112June 3, 2010Number 22

61

62

63 REPROGRAMACIÓN CELULAR Y ENFERMEDAD CARDIOVASCULAR

64 Clinical Implications of Basic Research Reprogramming Fibroblasts into Cardiomyocytes Charles E. Murry, M.D., Ph.D., and William T. Pu, M.D. N Engl J Med 2011; 364:177-17

65 The Path from Fibroblast to Cardiomyocyte. Murry CE, Pu WT. N Engl J Med 2011;364:177-178.

66

67

68

69

70

71

72

73 LA POBREZA Y ENFERMEDAD CARDIOVASCULAR

74

75

76

Download ppt "Comment www.thelancet.com www.thelancet.com Vol 377 February 12, 2011 Stemming the global tsunami of cardiovascular disease."

Similar presentations

Effect of a dietary Portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia Erin Woodard.

Effect of a dietary Portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia Erin Woodard.
Developing a Chronic Disease Model of Care for Coronary Artery Disease and Depression in Rural Settings Dr Steve Bunker Prof James Dunbar Dr Prasuna Reddy.

Developing a Chronic Disease Model of Care for Coronary Artery Disease and Depression in Rural Settings Dr Steve Bunker Prof James Dunbar Dr Prasuna Reddy.
Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:1264-72.

Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:
* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.
Frank B. Hu et al N Engl J Med 2004; 351: 2694- 703 Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.

Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.
INFLAMACION Y ENFERMEDAD CARDIOVASCULAR.

INFLAMACION Y ENFERMEDAD CARDIOVASCULAR.
Zacho J, et al. N Engl J Med 2008;359:1897-908 Risk of Ischemic Heart Disease as a Function of Plasma Levels of C-Reactive Protein (CRP) in the General.

Zacho J, et al. N Engl J Med 2008;359: Risk of Ischemic Heart Disease as a Function of Plasma Levels of C-Reactive Protein (CRP) in the General.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
Ridker PM, et al. Lancet 2009;373:1175-82. Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.

Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.
Charlotte Kragelund et al N Engl J Med 2005;352:666- 75 Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.
Relation between Cardiovascular Disease Risk Markers and Brain Infarcts Detected by Magnetic Resonance Imaging in an Elderly Population  Ruta Nylander,

Relation between Cardiovascular Disease Risk Markers and Brain Infarcts Detected by Magnetic Resonance Imaging in an Elderly Population  Ruta Nylander,
Genetic variation at chromosome 1p13

Genetic variation at chromosome 1p13
LDL cholesterol in CKD—to treat or not to treat?

LDL cholesterol in CKD—to treat or not to treat?
2013 ACC/AHA cholesterol treatment guidelines

2013 ACC/AHA cholesterol treatment guidelines
A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality  Rishi K. Wadhera,

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality  Rishi K. Wadhera,
Melody Sherwood, Peter A McCullough  The Lancet Global Health 

Melody Sherwood, Peter A McCullough  The Lancet Global Health 
Kerry-Anne Rye, Kwok Leung Ong  The Lancet Diabetes & Endocrinology 

Kerry-Anne Rye, Kwok Leung Ong  The Lancet Diabetes & Endocrinology 
Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
TNT: Baseline and final LDL cholesterol levels

TNT: Baseline and final LDL cholesterol levels

Similar presentations

Ads by Google